Decreased CSF-β-amyloid 42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of β-amyloid induced by disparate mechanisms

Dementia and Geriatric Cognitive Disorders

Volumn 13, Issue 2, 2002, Pages 112-118

  Sjögren, Magnus ^a   Davidsson, Pia ^a   Wallin, Anders ^a   Granérus, Ann Kathrine ^b   Grundström, Eva ^d   Askmark, Håkan ^d   Vanmechelen, Eugeen ^c   Blennow, Kaj ^a,e  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b University of Health Sciences   (Sweden)

^c INNOGENETICS   (Belgium)

^d UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^e MEDICAL RESEARCH COUNCIL   (Sweden)

Author keywords

Amyloid; Alzheimer's disease; Amyotrophic lateral sclerosis; Cerebrospinal fluid; Dementia; Frontotemporal; Hyperphosphorylated tau; Neurodegenerative; Tau

Indexed keywords

AMYLOID BETA PROTEIN; PHOSPHOPROTEIN; TAU PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FRONTOTEMPORAL DEMENTIA; HUMAN; MALE; NERVE FIBER DEGENERATION; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM;

AGED; AGED, 80 AND OVER; AGING; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYOTROPHIC LATERAL SCLEROSIS; DEMENTIA; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; PHOSPHORYLATION; TAU PROTEINS;

EID: 0036182732     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000048642     Document Type: Article

References (45)

1. Ageing and the dementias
2. Pathology-light microscopy of amyotrophic lateral sclerosis
3. The substantia nigra and parkinsonism
4. The pigment in the substantia nigra in parkinsonism. Microspectrophotometric comparison with other sources of human pigment
5. Tau protein in cerebrospinal fluid: A biochemical marker for axonal degeneration in Alzheimer disease?
6. Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: A community based follow up study
7. Apolipoprotein E genotyping and cerebrospinal fluid tau protein: Implications for the clinical diagnosis of Alzheimer's disease
8. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype
9. A population-based study of tau protein and ubiquitin in cerebrospinal fluid in 85-year-olds: Relation to severity of dementia and cerebral atrophy, but not to the apolipoprotein E4 allele
10. CSF levels of tau, B-amyloid42 and GAP-43 in frontotemporal dementia, other types of dementia and normal aging
11. Selective binding of soluble Abeta1-40 and Abeta1-42 to a subset of senile plaques
12. Full-length amyloid-beta (1-42(43)) and amino-terminally modified and truncated amyloid-beta 42(43) deposit in diffuse plaques
13. Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease
14. Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF
15. The level of cerebrospinal fluid tau correlates with neurofibrillary tangles in Alzheimer's disease
16. Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology
17. Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease
18. Decreased beta-amyloid1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jacob disease
19. Clinical and neuropathological criteria for frontotemporal dementia
20. Frontotemporal dementia can be distinguished from Alzheimer's disease and subcortical white matter dementia by an anterior to posterior rCBF-SPET ratio
21. Vascular dementia: Diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop
22. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis
23. The administration of guanidine in amyotrophic lateral sclerosis
24. Prevalence of dementia and regional brain syndromes in long-standing Parkinson's disease
25. 'Mini-mental State' A practical method for grading the cognitive state of patients for the clinician
26. Principles of Albumin and IgG analysis in neurological disorders
27. Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay
28. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: A sandwich ELISA with a synthetic phosphopeptide for standardization
29. Development of a specific diagnostic test for measurement of b-amyloid(1-42) in CSF
30. Approved recomendation on the theory of reference values. Part 5. Statistical treatment of collected reference values. Determination of reference limits
31. Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD
32. Tau protein in cerebrospinal fluid: A new diagnostic and prognostic marker in Alzheimer disease?
33. Tau antisera recognize neurofibrillary tangles in a range of neurodegenerative disorders
34. Neurofibrillary tangles of Guam parkinson-dementia are associated with reactive microglia and complement proteins
35. Evidence that the 42- and 40-amino acid forms of amyloid beta protein are generated from the beta-amyloid precursor protein by different protease activities
36. Axonal degeneration promotes abnormal accumulation of amyloid beta-protein in ascending gracile tract of gracile axonal dystrophy (GAD) mouse
37. Reactive astrocytes are widespread in the cortical gray matter of amyotrophic lateral sclerosis
38. Immunoreactivity of beta-amyloid precursor protein in amyotrophic lateral sclerosis
39. Pathological Tau proteins of Alzheimer's disease as a biochemical marker of neurofibrillary degeneration
40. Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17
41. Combined assessment of tau and neuronal thread protein in Alzheimer's disease CSF
42. Amyotrophic lateral sclerosis, Parkinson's disease and Alzheimer's disease: Phylogenetic disorders of the human neocortex sharing many characteristics
43. Neurodegenerative disease: A different view of diagnosis
44. Alzheimer's disease and Parkinson's disease: Distinct entities or extremes of a spectrum of neurodegeneration?